GMAB.CO in “The Patent Cliff Sparks a Biotech Land Grab”
Genmab A/S
Genmab combines validated antibody platforms, royalty income and wholly owned oncology assets, giving it leverage in licensing and acquisition negotiations.
GMAB.CO impact map — “The Patent Cliff Sparks a Biotech Land Grab”
How this story travels from the headline to GMAB.CO’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.
Loading GMAB.CO impact map…
Price history, marked with story events
Oct 20, 2025 – Oct 19, 2026 · 248 sessions
Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions
Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…
Full story
The Patent Cliff Sparks a Biotech Land Grab
Large drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.
BULL side — Genmab combines validated antibody platforms, royalty income and wholly owned oncology assets, giving it leverage in licensing and acquisition negotiations.
Read the full The Patent Cliff Sparks a Biotech Land Grab storyBull side
2 stories- China Becomes Pharma's Global R&D Engine
GMAB.CO in “China Becomes Pharma's Global R&D Engine”
FadingExposure: not rated yetWestern drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
Genmab’s acquisition of ProfoundBio added China-origin antibody-drug conjugate technology and clinical assets to its global oncology portfolio.
- Viewing
GMAB.CO in “The Patent Cliff Sparks a Biotech Land Grab”
FadingExposure: not rated yetLarge drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.
Genmab combines validated antibody platforms, royalty income and wholly owned oncology assets, giving it leverage in licensing and acquisition negotiations.
Bear side
1 story- America Imports the World's Drug Prices
GMAB.CO in “America Imports the World's Drug Prices”
StableExposure: not rated yetUS reference pricing puts global blockbuster economics—and not just American list prices—under pressure.
Genmab's valuation is supported by royalties and profit shares from drugs such as Darzalex and Epkinly, so lower benchmark prices would reduce downstream economics.